The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: A meta-analysis

Leukemia Research

Volumn 35, Issue 9, 2011, Pages 1170-1177

  Wang, Hao ^a   Chen, Xiao yuan ^b   Wang, Bai song ^a   Rong, Zheng xing ^a   Qi, Hong ^a   Chen, Hong zhuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Food and Drug Administration   (China)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; Chemotherapy; Clinical trial; Meta analysis

Indexed keywords

ARSENIC TRIOXIDE; RETINOIC ACID;

ARTICLE; BONE PAIN; CANCER MORTALITY; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; EDEMA; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HYPERGLYCEMIA; HYPERLEUKOCYTOSIS; HYPOKALEMIA; INFECTION; LEUKEMIA REMISSION; LEUKOCYTOSIS; LIVER DYSFUNCTION; META ANALYSIS; NEUROPATHY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL RATE; SYSTEMATIC REVIEW; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CHILD; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OXIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRETINOIN; YOUNG ADULT;

EID: 80051473507     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.06.002     Document Type: Article

References (36)

1. Ferrara F. Acute promyelocytic leukemia: what are the treatment options?. Expert Opin Pharmacother 2010, 11(4):587-596.
2. Zhou G.B., Zhao W.L., Wang Z.Y., Chen S.J., Chen Z. Retinoic acid and arsenic for treating acute promyelocytic leukemia. PLoS Med 2005, 2:e12.
3. Wang Z.Y., Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-2515.
4. Tallman M.S. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol 2007, 20:57-65.
5. Sun H.D., Ma L., Hu X.C., Zhang T. Treatment of acute promylocytic leukemia by AiLing-1 therapy. Zhong Xi Yi Jie He Xue Bao 1992, 12:170-172.
6. Shen Z.X., Chen G.Q., Ni J.H., Li X.S., Xiong S.M., Qiu Q.Y., et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
7. Soignet S.L., Frankel S.R., Douer D., Tallman M.S., Kantarjian H., Calleja E., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001, 19:3852-3860.
8. Gore S.D., Gojo I., Sekeres M.A., Morris L., Devetten M., Jamieson K., et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 2010, 28(6):1047-1053.
9. Powell B.L., Moser B., Stock W., Gallagher R.E., Willman C.L., Stone R.M., et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010, 116(19):3751-3757.
10. Zhang X.W., Yan X.J., Zhou Z.R., Yang F.F., Wu Z.Y., Sun H.B., et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010, 328(5975):240-243.
11. Estey E., Garcia-Manero G., Ferrajoli A., Faderl S., Verstovsek S., Jones D., et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006, 107:3469-3473.
12. Ravandi F., Estey E., Jones D., Faderl S., O'Brien S., Fiorentino J., et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009, 27(4):504-510.
13. Raffoux E., Rousselot P., Poupon J., Daniel M.T., Cassinat B., Delarue R., et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003, 21:2326-2334.
14. Shen Z.X., Shi Z.Z., Fang J., Gu B.W., Li J.M., Zhu Y.M., et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004, 101:5328-5335.
15. Xu S.N., Chen J.P., Liu J.P., Xia Y. Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis. Zhong Xi Yi Jie He Xue Bao 2009, 7(11):1024-1034.
16. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
17. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
18. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
19. Hozo S.P., Djulbegovic B., Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 5(1):13.
20. Hu J., Shen Z.X., Sun G.L., Chen S.J., Wang Z.Y., Chen Z. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. Int J Hematol 1999, 70:248-260.
21. Li X., Zhao Y.Z., Li Z.J., Yang R.C., Han M.Z., Qiu L.G. The effects of different post-remission treatment on long-term survival of acute promyelocytic leukemia. Zhonghua Nei Ke Za Zhi 2006, 45:741-743.
22. Li X., Zhao Y.Z., Li Z.J., Li Y.T., Li Y., Wan C.C., et al. Long-term survival analysis in 170 cases of acute promyelocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006, 14(3):437-441.
23. Li X., Sun W.J., Li Z.J., Zhao Y.Z., Li Y.T., Li Y., et al. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center. Leuk Res 2007, 31:765-771.
24. Zhong Y.L. The clinical study on Integrated Chinese and Western Medicine for the treatment of acute promyelocytic leukemia. Neimenggu Zhong Yi Yao 2008, 3:29-30.
25. Zhang L., Zhao H., Zhu X., Chen Y., Zou Y., Chen X. Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: a single center experience. Pediatr Blood Cancer 2008, 51:210-215.
26. Aribi A., Kantarjian H.M., Estey E.H., Koller C.A., Thomas D.A., Kornblau S.M., et al. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 2007, 109:1355-1359.
27. Wang G.J., Li W., Cui J.W., Gao S.J., Yao C., Jiang Z.Y., et al. Therapeutic effects of combination of arsenic trioxide with low-dose all-trans retinoic acid on induction of remission acute promyeloeytic leukemia. Zhonghua Yi Xue Za Zhi 2005, 85:1093-1096.
28. Jin H.S., Lu Y.X., Mu L.X. A comparision analysis of therapeutic effects in treating acute promyelocytic leukemia with all-trans retinoic acid, arsenic trioxide and chemotherapy. Zhong Guo Xian Dai Yi Xue Za Zhi 2007, 17:1744-1746.
29. Wang G., Li W., Cui J., Gao S., Yao C., Jiang Z., et al. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol Oncol 2004, 22:63-71.
30. Niu C., Yan H., Yu T., Sun H.P., Liu J.X., Li X.S., et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94:3315-3324.
31. Su X.L., Xia W.L. Combined treatment of All-trans-retinoic acid and arsenic trioxide in patients with new-diagnosed acute promyelocytic leukemia. Lin Chuan Yu Shi Jian 2006, 10:338-339.
32. Bai X.C., Ma Y., Song G.Q. The Combination treatment of arsenic trioxide and All-trans-retinoic acid in patients with acute promyelocytic leukemia. Ning Xia Yi Xue Yuan Xue Bao 2007, 29:502-504.
33. Li Z.C., Zou P., Zhao J., Fu H.J., Su M.D., Liu X.D. Clinical observation of the combination of all-trans retinoic acid with arsenic trioxide on newly diagnosed patients of acute promyelocytic leukemia. Lin Chuang Xue Ye Xue Za Zhi 2008, 21:481-548.
34. Douer D. ATO: the forefront of APL treatment?. Blood 2006, 107:2588-2589.
35. Zhou G.B., Zhang J., Wang Z.Y., Chen S.J., Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci 2007, 362:959-971.
36. Hu J., Liu Y.F., Wu C.F., Xu F., Shen Z.X., Zhu Y.M., et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009, 106:3342-3347.